查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1906009

醫用氣體及設備：市場佔有率分析、產業趨勢及統計、成長預測（2026-2031）

Medical Gases And Equipment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計醫用氣體和設備市場將從 2025 年的 180.2 億美元成長到 2026 年的 192.9 億美元，到 2031 年將達到 271.1 億美元，2026 年至 2031 年的複合年成長率為 7.03%。

醫用氣體和設備市場-IMG1

人口老化帶來的治療需求不斷成長、新冠疫情后醫院基礎設施的持續升級以及攜帶式製氧機技術的快速創新，共同推動了醫用氣體和設備市場的持續擴張。政府支持的氧氣供應穩定計劃、穿戴式感測器的微型化以及低全球暖化潛值（GWP）麻醉氣體混合物的商業化，進一步促進了需求成長。同時，綜合氣體供應商正利用規模經濟優勢，與各大急診護理機構簽訂長期合約。設備製造商市場依然分散，這為透過收購來深化產品系列、建構地域多元化的服務網路提供了空間，尤其是在高速成長的亞太市場。居家醫療的持續發展，推動了對氣瓶充裝、小規模現場製氧以及基於人工智慧的監測的需求，這些因素共同塑造了醫用氣體和設備市場的競爭格局。

全球醫用氣體及設備市場趨勢與展望

對居家醫療和床邊氧氣療法的需求不斷成長

聯邦醫療保險（Medicare）的36個月租賃框架支持可預測的報銷，鼓勵醫療服務提供者投資攜帶式設備，並提高患者對家庭氧氣療法的接受度。 FlexO2流量選擇器等技術使用戶主導調節次數加倍，並且自臨床應用以來，患者的感知活動能力評分提高了80分。配備最佳化沸石床的攜帶式製氧機氧氣精度現已達到98.68%，縮小了與固定式系統的性能差距。家庭護理領域13.01%的複合年成長率表明，這些改進與患者對熟悉環境的偏好相符。 2025年居家照護服務中心（CMS）的支付改革將使居家醫療費用增加2.5%，這將進一步推動分散式照護模式的發展。林德公司針對睡眠呼吸中止症患者的AIRGENIOUS試點計畫降低了持續性正壓呼吸器（CPAP）治療的依從性，並證明了預測分析在提高慢性病照護遵從性方面的有效性。

呼吸系統疾病呈上升趨勢

慢性阻塞性肺病（COPD）仍是導致病人需要吸氧住院的主要原因，佔三級醫院呼吸科病房病人總數的44.5%。典型的床位氣體需求量平均每年為350立方公尺氧氣和325立方公尺醫用空氣，並且隨著出院病患人數和手術量的增加呈線性成長。歐洲規劃者已將醫用氣體系統升級納入國家呼吸系統策略，正如奧地利2025年總體規劃所概述的。對疫情期間需求激增的分析表明，氧氣消費量增加了高達20倍，凸顯了供應基礎設施永久性冗餘的必要性。波蘭的「醫療需求地圖」舉措展示了呼吸系統疾病地圖如何指導醫院層面的氣體系統投資。

嚴格遵守多司法管轄區的cGMP和藥典要求

美國食品藥物管理局（FDA）的最終規則將於2025年12月生效，屆時將要求醫用氣體供應商全面遵守現行藥品生產品質管理規範（cGMP）和標籤通訊協定，並需投資更新其填充和分析系統。香港將於2026年6月起將醫用氣體歸類為藥品，並引進新的經銷商許可製度。同時，相關修訂將協調基於ISO標準的醫療設備品管與cGMP的細化，以增加跨境規成本為代價，促進全球標準的趨同。

細分市場分析

到2025年，純醫用氣體將佔醫用氣體和設備市場的37.12%，這反映了其在從醫院到家庭護理等各種治療應用中的重要性。受居家醫療日益普及和呼吸系統疾病發病率上升的推動，氧氣預計將以8.82%的複合年成長率成長。醫用空氣、二氧化碳、氦氣和特種氣體可用於手術充氣、診斷和磁振造影，但氦氣供應的波動導致價格上漲，對醫院預算造成壓力。加州大學舊金山分校（UCSF）成功地將氧化亞氮的消耗量減少了80-90%，促使各醫療機構轉向使用攜帶式氣瓶，以減少管道連接和廢棄物排放。

配套的醫用氣體設備涵蓋壓縮機、氣瓶以及管道監測系統等。阿特拉斯·科普柯於2023年收購Medi-teknique，便是產業整合旨在拓展服務範圍和持續維護收入的一個例證。 Beacon Medies的全球分銷網路將真空和歧管系統整合到新建醫院中，並透過多模光纖環網實現即時警報功能。日益成長的永續性意識正推動醫院採用低全球暖化潛勢（GWP）的麻醉氣體混合物。由於DESFLURANE的全球暖化潛勢值顯著低於地氟烷，歐洲監管機構建議使用SEVOFLURANE，這迫使供應商重新設計揮發性氣體的回收和清除系統。

儘管到2025年，包裝式氧氣瓶仍將保持45.05%的市場佔有率，但受患者對移動性需求以及醫療機構對經濟高效的慢性病護理模式的重視，可攜式製氧機預計將以每年9.67%的速度成長。德克薩斯農工大學的計算設計表明，動態沸石成分可以調節氧氣流量以滿足患者不斷變化的需求，從而在不犧牲純度的前提下減輕重量。同時，林德公司在2024年獲得了59份小規模現場製氧設備訂單，這反映出醫院對自主型氧氣供給能力的興趣，以應對供應中斷的情況。

大型三級醫院為了追求可預測的單位成本，仍然傾向於現場批量生產，而需要超高純度醫用氣體的專科醫療中心則更傾向於液態批量供應。持續的鋼瓶備用需求確保了所有治療方式的穩定需求，從而鞏固了醫用氣體和設備市場的多元化收入來源。

區域分析

北美地區預計到2025年將佔全球收入的35.25%，這得益於其成熟的支付系統、嚴格的FDA監管以及攜帶式製氧機的廣泛應用。隨著醫院透過現場儲氧罐維持氧氣供應的冗餘，以及CMS不斷完善報銷機制，居家醫療的普及率持續成長。該地區的設備供應商受益於清晰的監管路徑，該路徑既認可創新，又避免了模糊的市場進入規則。

亞太地區預計將以13.19%的複合年成長率成長，在所有地區中位居榜首，這主要得益於大規模醫院擴建、人口老齡化以及政府對醫療基礎設施的大力投入。印度計畫新增17,800張病床，並制定了價值500億美元的醫療設備藍圖，顯示管道系統和氣瓶的需求可能激增。中國自2024年起實施的扶持性採購政策預計將在2025年提振醫療設備支出，進一步鞏固該地區作為關鍵成長引擎的地位。林德和梅塞爾在印度和東南亞地區的空氣分離裝置擴建項目，體現了供應商致力於維護區域供應穩定的決心。

歐洲仍然是關鍵市場，這主要得益於嚴格的環境法規，這些法規正在加速低全球暖化潛勢（GWP）麻醉劑的普及應用。英國國民醫療服務體系（NHS）逐步淘汰地DESFLURANE的舉措在整個歐洲大陸產生了連鎖反應，迫使供應商改變配方，並促使醫院升級復甦室系統。液化空氣集團在法國、德國和巴西簽訂的低碳氧氣供應合約凸顯了範圍3排放在公立醫院採購標準中日益成長的重要性。

中東/非洲和南美洲都是具有高潛力的早期市場。對三級醫療機構的投資以及藥典標準的逐步統一將創造新的機遇，但經濟波動和分散的報銷體系將限制短期內的擴張。

其他福利：

  • Excel格式的市場預測（ME）表
  • 3個月的分析師支持

目錄

第1章 引言

  • 研究假設和市場定義
  • 調查範圍

第2章調查方法

第3章執行摘要

第4章 市場情勢

  • 市場概覽
  • 市場促進因素
    • 對居家醫療和床邊氧氣療法的需求不斷成長
    • 呼吸系統疾病呈上升趨勢
    • 新冠疫情後政府資助的氧氣基礎設施
    • 攜帶式和穿戴式式濃度設備和感測器的微型化
    • 環境友善、低全球暖化潛值麻醉氣體混合物的商業化
    • 基於人工智慧的天然氣管道預測監測和庫存管理
  • 市場限制
    • 嚴格遵守多司法管轄區的cGMP和藥典要求
    • 長期家庭氧氣療法的報銷有限
    • 散裝氣體處理中的職場安全責任和保險成本。
    • 氦氣供應的不確定性推高了特種氣體成本
  • 波特五力分析
    • 新進入者的威脅
    • 買方/消費者的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭對手之間的競爭

第5章 市場規模及成長預測（金額：美元）

  • 依產品
    • 醫用氣體
      • 純醫用氣體
        • 氧
        • 氧化亞氮
        • 醫用空氣
        • 二氧化碳
        • 氦氣和特種氣體
      • 醫用氣體混合物
      • 生物環境
    • 醫用氣體設備
      • 壓縮機
      • 圓柱
      • 軟管組件和閥門
      • 面罩和套管
      • 吸力系統
      • 歧管和管路系統
      • 警報和監控系統
  • 按模式
    • 大規模現場發電
    • 包裝汽缸
    • 液體/散裝貨物運輸
    • 可攜式製氧機
  • 透過使用
    • 治療
    • 診斷和影像
    • 製藥生產與研究
    • 冷凍手術和冷凍療法
    • 居家醫療
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 居家照護環境
    • 學術和研究機構
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 亞太其他地區
    • 中東和非洲
      • GCC
      • 南非
      • 其他中東和非洲地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章 競爭情勢

  • 市場集中度
  • 市佔率分析
  • 公司簡介
    • Linde plc
    • Air Liquide
    • Air Products & Chemicals
    • Messer Group
    • Taiyo Nippon Sanso
    • Atlas Copco
    • BeaconMedaes
    • Amico Group
    • Matheson Tri-Gas
    • GCE Group
    • NOVAIR
    • Luxfer Gas Cylinders
    • Getinge AB
    • Dragerwerk AG
    • INOX Air Products
    • South African Oxygen（Afrox）
    • Gulf Cryo
    • Coregas Pty
    • SOL Group
    • Air Water Inc.
    • Invacare Corporation

第7章 市場機會與未來展望

簡介目錄
Product Code: 50695

The Medical Gases And Equipment Market is expected to grow from USD 18.02 billion in 2025 to USD 19.29 billion in 2026 and is forecast to reach USD 27.11 billion by 2031 at 7.03% CAGR over 2026-2031.

Medical Gases And Equipment - Market - IMG1

Rising therapeutic demand from aging populations, steady hospital infrastructure upgrades after COVID-19, and rapid innovation in portable concentrators underpin sustained expansion of the medical gases and equipment market. Government-supported oxygen resilience projects, miniaturization of wearable sensors, and the commercialization of low-GWP anesthetic blends further reinforce volume growth, while consolidated gas suppliers leverage scale to secure long-term contracts across acute-care settings. Equipment makers remain fragmented, creating space for bolt-on acquisitions that deepen product portfolios and geographically diversified service footprints, especially in high-growth Asia-Pacific markets. The continued shift toward home-based care amplifies cylinder refilling, small on-site generation, and AI-enabled monitoring demand, collectively shaping the competitive contours of the medical gases and equipment market.

Global Medical Gases And Equipment Market Trends and Insights

Rising Demand for Home Healthcare & POC Oxygen Therapy

Medicare's 36-month rental framework underpins predictable reimbursement, encouraging supplier investment in portable devices and reinforcing patient acceptance of at-home oxygen therapy.Technology such as FlexO2 flow selectors has doubled user-initiated adjustments, raising perceived activity capacity scores by 80 points after clinical deployment.Portable concentrators that use optimized zeolite beds now deliver 98.68% oxygen accuracy, narrowing the performance gap with stationary systems. A 13.01% CAGR in the home-care segment illustrates how these improvements align with patient preference for familiar environments. CMS's 2025 payment update, lifting home health rates by 2.5% adds further momentum to decentralized care models. Linde's AIRGENIOUS pilot among sleep-apnea users cut CPAP non-compliance, showcasing predictive analytics for chronic-care adherence.

Growing Prevalence of Respiratory Diseases

COPD remains the chief driver of oxygen admissions, representing 44.5% of respiratory ward volume in tertiary hospitals. Typical bed-based gas demand averages 350 m3 oxygen and 325 m3 medical air each year, scaling directly with discharge volumes and surgical intensity. European planners have already embedded medical gas system upgrades into national respiratory strategies, as shown in the Austrian Masterplan 2025. Analysis of pandemic surges revealed oxygen consumption rising up to 20-fold, anchoring the need for permanent redundancy in supply infrastructure. Poland's Maps of Health Needs initiative highlights how respiratory disease mapping guides investment in gas systems at hospital level.

Stringent Multi-Jurisdictional cGMP & Pharmacopeia Compliance

The FDA's final rule, effective December 2025, mandates full current good manufacturing practice and labeling protocols for medical gases, compelling suppliers to invest in upgraded filling and analytical systems. Hong Kong will classify medical gases as pharmaceutical products from June 2026, introducing a new licensing layer for distributors. Parallel amendments harmonize ISO-based device quality management with cGMP clarifications, raising cross-border compliance costs yet fostering global standard convergence.

Other drivers and restraints analyzed in the detailed report include:

  1. Government-Funded Oxygen Infrastructure Build-Outs Post-COVID
  2. Miniaturization of Portable/Wearable Concentrators & Sensors
  3. Limited Reimbursement for Long-Term Home Oxygen Therapy

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Pure Medical Gases captured 37.12% of the medical gases and equipment market in 2025, reflecting indispensable therapeutic use across hospitals and home settings. Oxygen is projected to record an 8.82% CAGR, aided by expanding home-care adoption and respiratory disease prevalence. Medical Air, Carbon Dioxide, and Helium & Specialty Gases serve surgical insufflation, diagnostics, and MRI needs, though helium supply volatility has driven price escalations that strain hospital budgets. Nitrous Oxide consumption is shifting toward portable cylinders as institutions remove piped lines to curb waste, following UCSF's 80-90% reduction success.

Complementary medical gas equipment ranges from compressors and cylinders to pipeline monitoring systems. Atlas Copco's 2023 Medi-teknique acquisition illustrates consolidation aimed at service breadth and recurring maintenance revenue. BeaconMedaes' global distributor network embeds vacuum and manifold systems within new hospital builds, leveraging multi-mode optical fiber ring networks for real-time alarm capabilities. A rising focus on sustainability is prompting hospitals to adopt low-GWP anesthetic blends. European regulators endorse sevoflurane over desflurane because of its far lower global-warming potential, nudging suppliers to re-engineer recovery and scavenging systems for volatile agents.

Packaged Cylinders retained a 45.05% share in 2025, yet Portable Concentrators are forecast to grow 9.67% annually as patients demand mobility and healthcare providers emphasize cost-effective chronic-care models. Computational design by Texas A&M shows that dynamic zeolite configurations can tailor oxygen flow to fluctuating patient needs, reducing weight without cutting purity. Meanwhile, Linde recorded 59 small on-site plant wins in 2024, reflecting hospital interest in self-reliant oxygen capacity to hedge against supply disruptions.

Bulk on-site generation continues to attract large tertiary hospitals seeking predictable unit costs, whereas liquid bulk delivery supports specialty centers with ultra-high purity requirements. The continued preference for cylinder backup ensures steady demand across every modality, cementing a diversified revenue mix within the medical gases and equipment market.

The Medical Gases and Equipment Market Report is Segmented by Product (Medical Gases [Pure Medical Gases, and More], and Medical Gas Equipment [Compressors, and More]), Modality (Bulk On-Site Generation, and More), Application (Therapeutic, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America contributed 35.25% of 2025 revenue, anchored by mature payer systems, strict FDA oversight, and widespread adoption of portable concentrators. Hospitals maintain redundant oxygen generation backed by on-site bulk tanks, while home-care penetration continues to rise as CMS refines reimbursement. Regional equipment vendors benefit from clear regulatory pathways that reward innovation without ambiguous market access rules.

Asia-Pacific is projected to grow at 13.19% CAGR, the highest among all regions, driven by large-scale hospital expansion, aging populations, and proactive government funding for medical infrastructure. India's planned capacity additions of 17,800 beds alongside a USD 50 billion medical device roadmap illustrate the underlying demand surge for pipeline systems and cylinders. China's supportive procurement policies post-2024 are expected to unlock medical device spending in 2025, reinforcing the region's status as the foremost growth engine. Air separation unit expansions by Linde and Messer across India and Southeast Asia signal supplier commitment to sustaining regional supply security.

Europe remains a major market, propelled by stringent environmental mandates that accelerate low-GWP anesthesia adoption. The NHS elimination of desflurane has cascaded across continental practice, compelling suppliers to reformulate and hospitals to upgrade recovery systems. Air Liquide's low-carbon oxygen supply contracts in France, Germany, and Brazil showcase the rising importance of Scope 3 emissions in public hospital procurement criteria.

Middle East & Africa and South America collectively represent high-potential but early-stage markets. Investments in tertiary care facilities and the gradual harmonization of pharmacopeia standards will unlock incremental opportunities, although economic volatility and reimbursement fragmentation temper near-term scale.

  1. Linde plc
  2. Air Liquide
  3. Air Products & Chemicals
  4. Messer Group
  5. Taiyo Nippon Sanso
  6. Atlas Copco
  7. Beckton Dickinson
  8. Amico Group
  9. Matheson Tri-Gas
  10. GCE Group
  11. NOVAIR
  12. Luxfer Gas Cylinders
  13. Getinge
  14. Dragerwerk AG
  15. INOX Air Products
  16. South African Oxygen (Afrox)
  17. Gulf Cryo
  18. Coregas Pty
  19. SOL Group
  20. Air Water Inc.
  21. Invacare

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Home Healthcare & POC Oxygen Therapy
    • 4.2.2 Growing Prevalence of Respiratory Diseases
    • 4.2.3 Government-Funded Oxygen Infrastructure Build-Outs Post-COVID
    • 4.2.4 Miniaturization of Portable/ Wearable Concentrators & Sensors
    • 4.2.5 Commercialization of Eco-Friendly Low-GWP Anaesthesia Gas Blends
    • 4.2.6 AI-Enabled Predictive Gas-Pipeline Monitoring & Inventory Control
  • 4.3 Market Restraints
    • 4.3.1 Stringent Multi-Jurisdictional cGMP & Pharmacopeia Compliance
    • 4.3.2 Limited Reimbursement for Long-Term Home Oxygen Therapy
    • 4.3.3 Workplace-Safety Liability & Insurance Costs for Bulk-Gas Handling
    • 4.3.4 Helium Supply Volatility Driving Up Specialty-Gas Costs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Product
    • 5.1.1 Medical Gases
      • 5.1.1.1 Pure Medical Gases
        • 5.1.1.1.1 Oxygen
        • 5.1.1.1.2 Nitrous Oxide
        • 5.1.1.1.3 Medical Air
        • 5.1.1.1.4 Carbon Dioxide
        • 5.1.1.1.5 Helium & Specialty Gases
      • 5.1.1.2 Medical Gas Mixtures
      • 5.1.1.3 Biological Atmosphere
    • 5.1.2 Medical Gas Equipment
      • 5.1.2.1 Compressors
      • 5.1.2.2 Cylinders
      • 5.1.2.3 Hose Assemblies & Valves
      • 5.1.2.4 Masks & Cannulas
      • 5.1.2.5 Vacuum & Suction Systems
      • 5.1.2.6 Manifold & Pipeline Systems
      • 5.1.2.7 Alarm & Monitoring Systems
  • 5.2 By Modality
    • 5.2.1 Bulk On-site Generation
    • 5.2.2 Packaged Cylinders
    • 5.2.3 Liquid/Bulk Delivery
    • 5.2.4 Portable Concentrators
  • 5.3 By Application
    • 5.3.1 Therapeutic
    • 5.3.2 Diagnostic & Imaging
    • 5.3.3 Pharmaceutical Manufacturing & Research
    • 5.3.4 Cryosurgery & Cryotherapy
    • 5.3.5 Home Healthcare
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Surgical Centers
    • 5.4.3 Home Care Settings
    • 5.4.4 Academic & Research Institutes
  • 5.5 By Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Linde plc
    • 6.3.2 Air Liquide
    • 6.3.3 Air Products & Chemicals
    • 6.3.4 Messer Group
    • 6.3.5 Taiyo Nippon Sanso
    • 6.3.6 Atlas Copco
    • 6.3.7 BeaconMedaes
    • 6.3.8 Amico Group
    • 6.3.9 Matheson Tri-Gas
    • 6.3.10 GCE Group
    • 6.3.11 NOVAIR
    • 6.3.12 Luxfer Gas Cylinders
    • 6.3.13 Getinge AB
    • 6.3.14 Dragerwerk AG
    • 6.3.15 INOX Air Products
    • 6.3.16 South African Oxygen (Afrox)
    • 6.3.17 Gulf Cryo
    • 6.3.18 Coregas Pty
    • 6.3.19 SOL Group
    • 6.3.20 Air Water Inc.
    • 6.3.21 Invacare Corporation

7 Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment